Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02379377 · ClinicalTrials.gov registry record · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
A Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT02379377 is a Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02379377, a Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Fluorine F 18 L-glutamate Derivative 18F-FSPG
- BIOLOGICAL Carbon C 11 Acetate
- BIOLOGICAL Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02379377
The ClinicalTrials.gov registry entry for NCT02379377 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT02379377 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02379377 about?
NCT02379377 is a clinical study titled "18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant". This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out h...
What is the current status of trial NCT02379377?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2022-02-15. Estimated completion is 2027-05-31.
What conditions does trial NCT02379377 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Resectable Hepatocellular Carcinoma, Benign Liver Tumor, Adult Hepatocellular Carcinoma, Metastases to Liver.
What interventions are being tested in trial NCT02379377?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fluorine F 18 L-glutamate Derivative 18F-FSPG (BIOLOGICAL), Carbon C 11 Acetate (BIOLOGICAL), Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose (BIOLOGICAL).
Who is sponsoring clinical trial NCT02379377?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02379377 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.